MabVax Therapeutics (OTCMKTS:MBVX) Has A Bloody Start Of The Month

[[tagnumber 0]][[tagnumber 1]]MabVax Therapeutics (OTCMKTS:MBVX) has had quite an eventful year so far. The progress that the company is making and the people who are getting involved with [[tagnumber 2]]MBVX[[tagnumber 3]] have managed to provide for some pretty interesting trading that pushed the ticker above $4 per share earlier this year.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]After the increase, in both value and daily volumes, that the ticker experienced things quieted down a bit and [[tagnumber 2]]MBVX[[tagnumber 3]] began to slide downhill. Volumes picked up once again in the beginning of July once again after investors were reminded about the $12 million investment made in the company by Dr. Phillip Frost and Opko Health, Inc. (NYSE:OPK).[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]After all, despite having recorded some pretty decent financials in the first quarter of the year the company did need funding in order to continue with its operations. Here is a quick reminder of what [[tagnumber 2]]MBVX[[tagnumber 3]] had to show for the quarter ended March 31, 2015.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 19]] [[tagnumber 20]]cash: $4.73 million[[tagnumber 21]] [[tagnumber 20]]current assets: $5.28 million[[tagnumber 21]] [[tagnumber 20]]current liabilities: $3.93 million[[tagnumber 21]] [[tagnumber 20]]quarterly revenues: $239 thousand[[tagnumber 21]] [[tagnumber 20]]quarterly net loss: $2.44 million[[tagnumber 21]] [[tagnumber 20]] [[tagnumber 21]] [[tagnumber 32]] [[tagnumber 0]]Considering these numbers and the fact that [[tagnumber 2]]MBVX[[tagnumber 3]] has the favor of Dr. Frost and OPK the current market cap of around $42 million seems a bit low when you compare it to other pharmaceutical companies that have far less to boast about.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]Still, this hasn’t stopped [[tagnumber 2]]MBVX[[tagnumber 3]] from sliding down the charts in the first sessions of the month. Despite an optimistic letter to shareholders from yesterday we saw the ticker lose 7.37% during the session and finish with a price of $1.76 and a total of 58 thousand traded shares that generated a mere $107 thousand in daily dollar volume.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]We see that the ticker is more stable in today’s trading so the slide might have come to an end. This, however, doesn’t mean that you should skip on doing your due diligence and weighing out the risks before putting any money on the line.[[tagnumber 4]]